| # | Drug | Count |
|---|---|---|
| 0 | LENALIDOMIDE | 331 |
| 1 | DEXAMETHASONE | 198 |
| 2 | DEXAMETHASONE 1.5 MG | 198 |
| 3 | CYCLOPHOSPHAMIDE | 170 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 170 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 170 |
| 6 | BLINATUMOMAB | 139 |
| 7 | BORTEZOMIB | 110 |
| 8 | FLUDARABINE PHOSPHATE | 65 |
| 9 | DOXORUBICIN | 61 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BLINATUMOMAB | 139 | 0.0130 |
| 1 | DEXTROSE AND SODIUM CHLORIDE | 2 | 0.0120 |
| 2 | INOTUZUMAB OZOGAMICIN | 34 | 0.0114 |
| 3 | ERAVACYCLINE | 2 | 0.0067 |
| 4 | NALBUPHINE HYDROCHLORIDE | 1 | 0.0044 |
| 5 | BRODALUMAB | 7 | 0.0034 |
| 6 | DASATINIB | 23 | 0.0025 |
| 7 | ASCIMINIB | 8 | 0.0023 |
| 8 | MELPHALAN HYDROCHLORIDE | 54 | 0.0021 |
| 9 | ISRADIPINE | 1 | 0.0018 |
| # | Drug class | Count |
|---|---|---|
| 0 | Thalidomide Analog [EPC] | 332 |
| 1 | Corticosteroid [EPC] | 241 |
| 2 | Alkylating Drug [EPC] | 182 |
| 3 | Proteasome Inhibitor [EPC] | 115 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 52 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 46 |
| 6 | CD22-directed Immunoconjugate [EPC] | 34 |
| 7 | Platinum-based Drug [EPC] | 26 |
| 8 | Topoisomerase Inhibitor [EPC] | 26 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 20 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD22-directed Immunoconjugate [EPC] | 34 | 0.0114 |
| 1 | Interleukin-17 Receptor A Antagonist [EPC] | 7 | 0.0034 |
| 2 | CD38-directed Cytolytic Antibody [EPC] | 10 | 0.0017 |
| 3 | Proteasome Inhibitor [EPC] | 115 | 0.0010 |
| 4 | Carnitine Analog [EPC] | 3 | 0.0008 |
| 5 | Alkylating Drug [EPC] | 182 | 0.0007 |
| 6 | Nucleoside Analog Antifungal [EPC] | 1 | 0.0007 |
| 7 | Lipid-based Polyene Antifungal [EPC] | 9 | 0.0007 |
| 8 | Thalidomide Analog [EPC] | 332 | 0.0006 |
| 9 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 3 | 0.0006 |